Q3 2020

Filed Nov 6, 2020 · 10-Q · 37 days after period end · 0000886163-20-000122

Q3 2020 · 10-Q

Revenue

$41.85M

+68.7% vs Q3 2019

Net Income

-$6.70M

N/M vs Q3 2019

EPS Diluted

-$0.42

N/M vs Q3 2019

Operating Income$3,747,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2020	Q3 2019	Q3 2018	Q3 2017
Revenue	$41.85M	$24.81M	$45.66M	$45.66M
Net Income	-$6.70M	-$15.25M	$67.36M	$67.36M
EPS Diluted	-$0.42	-$0.81	$2.80	$2.80

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR